NCT01847391View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Ischemic Heart Disease

Interventions

DRUG

GS-6615

GS-6615 tablet(s) administered orally once daily

DRUG

Placebo

Placebo tablet(s) to match GS-6615 administered orally once daily

Trial Locations (1)

53704

Investigational Site, Madison

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01847391 - A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects | Biotech Hunter | Biotech Hunter